Similar approaches have now been applied to the screening of large cohorts of BRCA1/2 negative hereditary breast/ovarian cancer families finding mutations in non‐BRCA1/2 genes in 4–11% of the cases, depending on the features of the patients cohorts and/or on the size of the multigene panel 10, 11, 12, 13, 14, 15. This evidence concerns the gene BRCA1 and ovarian cancer.